1.Alkaptonuria with IgA nephropathy: a case report and literature review
Yingxin RUAN ; Tiekun YAN ; Jianqing JIANG ; Junya JIA
Chinese Journal of Nephrology 2023;39(8):624-627
The paper reports a rare case of alkaptonuria (AKU) with IgA nephropathy, and analyzes its clinical manifestations, imaging findings, pathological features, gene diagnosis and treatment process, so as to provide reference for the diagnosis and treatment of the disease. The clinical symptoms of the patient were mainly black urine, microscopic hematuria and proteinuria. Renal pathology showed mild mesangial hyperplasia IgA nephropathy, and renal tubular epithelial cytochrome deposition. Genetic analysis indicated that a pathogenic mutation was detected on the AKU-related homogentisate 1, 2-dioxygenase gene possibly associated with the phenotype of the patient. Genetic testing and renal pathology were effective methods to make a definite diagnosis for the case.
2.Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
Tingyan SHI ; Libing XIANG ; Jianqing ZHU ; Jihong LIU ; Ping ZHANG ; Huaying WANG ; Yanling FENG ; Tao ZHU ; Yingli ZHANG ; Aijun YU ; Wei JIANG ; Xipeng WANG ; Yaping ZHU ; Sufang WU ; Yincheng TENG ; Jiejie ZHANG ; Rong JIANG ; Wei ZHANG ; Huixun JIA ; Rongyu ZANG
Journal of Gynecologic Oncology 2022;33(4):e63-
3.Diagnostic accuracy and safety of Dermatophagoides pteronyssinus extracts used for skin prick test
Rui TANG ; Xiaohong LYU ; Yuxi LIU ; Ruiqi WANG ; Lianglu WANG ; Hong LI ; Jinlyu SUN ; Yuxiang ZHI ; Jianqing GU ; Kai GUAN ; Liping WEN ; Zixi WANG ; Lisha LI ; Le CUI ; Yingyang XU ; Junxiong ZHOU ; Tao XU ; Jia YIN
Chinese Medical Journal 2022;135(21):2563-2569
Background::Dermatophagoides pteronyssinus is a common allergen causing allergic diseases in China. The aim of this study was to evaluate the efficacy and safety of D. pteronyssinus extracts produced by Peking Union Medical College Hospital (PUMCH) for the skin prick test (SPT) in the diagnosis of D. pteronyssinus allergy. Methods::A total of 910 subjects with allergic diseases were prescribed D. pteronyssinus SPT and specific sIgE (sIgE) test among the Outpatients of Department of Allergy, PUMCH from August 10, 2015 to August 30, 2017. Receiver operating characteristic curve (ROC) analysis was performed according to the results of D. pteronyssinus-sIgE detection. The accuracy of D. pteronyssinus extracts used for SPT in the diagnosis of D. pteronyssinus allergy was evaluated under different cutoff values. Adverse events after SPT were recorded to evaluate safety. Results::There were 796 and 618 subjects in the full analysis set (FAS) and the per protocol set (PPS), respectively. The areas under the curve of FAS and PPS were 0.871 and 0.873, respectively. According to the ROC of PPS, the optimal and 95% specificity diagnostic cutoff values of D. pteronyssinus SPT mean wheal diameter were 3.25 and 3.75 mm, respectively. No adverse events occurred. Conclusion::The extracts of D. pteronyssinus for SPT were simple, highly accurate, and safe and should be considered for recommendation in the clinical diagnosis of D. pteronyssinus allergy.
4.Efficacy of Hormone Combined with Cyclophosphamide in the Treatment of Connective Tissue Disease-associated Interstitial Lung Disease and Analysis of Its Influential Factors
Jing SU ; Yating YANG ; Jujuan JIA ; Baoli XIANG ; Haihong QIAN ; Xuejun ZHI ; Chen LI ; Jianqing ZHAO
China Pharmacy 2021;32(12):1501-1505
OBJECTIVE:To investigate the efficacy of hormone combined with cyclophosphamide in the treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD)and to analyze its influential factors. METHODS :100 patients diagnosed as CTD-ILD in our hospital from Jan. 2018 to Jan. 2019 were randomly divided into observation group and control group ,with 50 cases in each group. Control group was treated with Compound cyclophosphamide tablets ,50 mg each time,3-4 times each day. Observation group was additionally treated with Prednisone acetate tablets ,10 mg each time ,3-4 times each day ,on the basis of control group. Treatment courses of 2 groups lasted for 6 months. The clinical efficacy ,the occurrence of ADR,lung function before and after treatment ,the levels of peripheral IL- 6,CRP and PCT and quality of life (SGRQ score )were compared between 2 groups. According to the therapeutic efficacy ,all patients were divided into effective group and ineffective group. The related factors influencing the clinical efficacy of CTD-ILD were analyzed by univariate and multivariate Logistic regression analysis. RESULTS :After treatment ,total response rate ,FVC,FEV1 and DLCO of observation group were significantly higher than those of control group ,while SGRQ score ,levels of IL- 6,CRP and PCT in peripheral blood were significantly lower than control group (P<0.05). There was no significant difference in the total incidence of ADR between 2 groups(P>0.05). Univariate analysis showed that there were no significant differences in gender ,age,past medical history and CTD type between effective group and ineffective group (P>0.05). However ,there were statistical significancant differences in the distribution of different levels of IL- 6,CRP and PCT in peripheral blood between 2 groups(P<0.05). Multivariate Logistic regression analysis showed that IL- 6 was an independent risk factor for therapeutic efficacy of combined therapy [OR (95%CI)= 4.537(3.668,10.352),P=0.002]. CONCLUSIONS :Hormone combined with cyclophosphamide can significantly improve the therapeutic efficacy of CTD-ILD patients ,improve their lung function and quality of life ,and reduce the expression level of inflammatory factors. The level of IL- 6 is an independent risk factor affecting the efficacy of the treatment ,and its changes should be paid close attention to during the treatment.
5.Interference of CD38 monoclonal antibody in blood compatibility testing and its countermeasures: A general consensus among experts
Jianqing MI ; Xiaohong CAI ; Shaoyuan WANG ; Lihua HU ; Ting NIU ; Deqing WANG ; Chengcheng FU ; Chunyan SUN ; Dong XIANG ; Wen GAO ; Tianhong MIAO ; Liye ZHONG ; Baohua QIAN ; Gang AN ; Rong XIA ; Rong GUI ; Jing LIU ; Xiaofeng TANG ; Jue XIE ; Jia GAN ; Jiang WU ; Danhui FU ; Li QIN ; Jian HOU ; Xuefeng WANG
Chinese Journal of Blood Transfusion 2021;34(4):327-334
With continuous discovery of tumor immune targets and continuous changes in antibody research and development technology, antibody drugs are becoming more and more widely used in clinical practice. However, some targets are not only expressed on tumor cells, but also on red blood cells. Therefore, the clinical application of antibodies against the corresponding targets may interfere with the detection of blood transfusion compatibility, resulting in difficulty in blood matching or delay of blood transfusion. This consensus summarizes the current solutions for the interference of CD38 monoclonal antibody (CD38 mAb) in transfusion compatibility testing. After analyzing the advantages and disadvantages of different methods, polybrene and sulfhydryl reducing agents [dithiothreitol (DTT) or 2-mercaptoethanol (2-Me)], as a solution for CD38 mAb interference in blood compatibility testing, are recommended for Chinese patients, so as to eliminate blood transfusion interference produce by CD38 mAb and further provide a pre-transfusion workflow for clinicians and technicians in Department of Blood Transfusion.
6.A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
Tingyan SHI ; Sheng YIN ; Jianqing ZHU ; Ping ZHANG ; Jihong LIU ; Libing XIANG ; Yaping ZHU ; Sufang WU ; Xiaojun CHEN ; Xipeng WANG ; Yincheng TENG ; Tao ZHU ; Aijun YU ; Yingli ZHANG ; Yanling FENG ; He HUANG ; Wei BAO ; Yanli LI ; Wei JIANG ; Ping ZHANG ; Jiarui LI ; Zhihong AI ; Wei ZHANG ; Huixun JIA ; Yuqin ZHANG ; Rong JIANG ; Jiejie ZHANG ; Wen GAO ; Yuting LUAN ; Rongyu ZANG
Journal of Gynecologic Oncology 2020;31(3):e61-
Background:
In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence.
Methods
SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cyclesof platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate.
7.Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
Rong JIANG ; Jianqing ZHU ; Jae-Weon KIM ; Jihong LIU ; Kazuyoshi KATO ; Hee-Seung KIM ; Yuqin ZHANG ; Ping ZHANG ; Tao ZHU ; Daisuke AOKI ; Aijun YU ; Xiaojun CHEN ; Xipeng WANG ; Ding ZHU ; Wei ZHANG ; Huixun JIA ; Tingyan SHI ; Wen GAO ; Sheng YIN ; Yanling FENG ; Libing XIANG ; Aikou OKAMOTO ; Rongyu ZANG
Journal of Gynecologic Oncology 2020;31(5):e86-
Background:
Two randomized phase III trials (EORTC55971 and CHORUS) showed similar progression-free and overall survival in primary or interval debulking surgery in ovarian cancer, however both studies had limitations with lower rate of complete resection and lack of surgical qualifications for participating centers. There is no consensus on whether neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) could be a preferred approach in the management of advanced epithelial ovarian cancer (EOC) in the clinical practice.
Methods
The Asian SUNNY study is an open-label, multicenter, randomized controlled, phase III trial to compare the effect of primary debulking surgery (PDS) to NACT-IDS in stages IIIC and IV EOC, fallopian tube cancer (FTC) or primary peritoneal carcinoma (PPC).The hypothesis is that PDS enhances the survivorship when compared with NACT-IDS in advanced ovarian cancer. The primary objective is to clarify the role of PDS and NACT-IDS in the treatment of advanced ovarian cancer. Surgical quality assures include at least 50% of no gross residual (NGR) in PDS group in all centers and participating centers should be national cancer centers or designed ovarian cancer section or those with the experience participating surgical trials of ovarian cancer. Any participating center should be monitored evaluating the proportions of NGR by a training set. The aim of the surgery in both arms is maximal cytoreduction. Tumor burden of the disease is evaluated by diagnostic laparoscopy or positron emission tomography/computed tomography scan. Patients assigned to PDS group will undergo upfront maximal cytoreductive surgery within 3 weeks after biopsy, followed by 6 cycles of standard adjuvant chemotherapy. Patients assigned to NACT group will undergo 3 cycles of NACT-IDS, and subsequently 3 cycles of adjuvant chemotherapy. The maximal time interval between IDS and the initiation of adjuvant chemotherapy is 8 weeks. Major inclusion criteria are pathologic confirmed stage IIIC and IV EOC, FTC or PPC; ECOG performance status of 0 to 2; ASA score of 1 to 2. Major exclusion criteria are non-epithelial tumors as well as borderline tumors; low-grade carcinoma; mucinous ovarian cancer. The sample size is 456 subjects. Primary endpoint is overall survival.
8.Application of self-management-oriented network platform in depression rehabilitation
Hongfen XIE ; Xiaoyan JI ; Guimei WANG ; Qimei HU ; Jianqing JIA ; Wei JIANG
Chinese Journal of Modern Nursing 2020;26(29):4072-4077
Objective:To explore the application and effects of the self-management-oriented network platform in depression rehabilitation.Methods:Totally 118 patients with depression discharged from a municipal mental health center and the communities that it governs between January and December 2017 were selected by convenient sampling and divided into the study group and the control group by Excel sheets, with 59 cases in each group, of which 2 cases dropped out from the study group. Patients in the control group received routine disease management, while patients in the study group received self-management and education via the depression network management platform after a personalized management plan was formulated upon discharge on this basis. After 6 months of intervention, the improvements in satisfaction, self-efficacy and suicidal risks were compared between the two groups.Results:After intervention, the satisfaction scores of visit time, visit attitude, visit content, and humanistic care of the study group were higher than those of the control group, and the differences were statistically significant ( P<0.05) ; the General Self-Efficacy Scale score of the study group was higher than that of the control group, and the difference was statistically significant ( P<0.05) ; the scores of despair, optimism, and sleep factors in suicidal ideation in the study group were lower than those of the control group, and the differences were statistically significant ( P<0.05) . Conclusions:The self-management-oriented network platform management model for discharged patients with depression can improve patient satisfaction, enhance their sense of self-efficacy, reduce the risk of suicide, and strengthen their self-management capabilities.
9.Clinical correlation between incipient C-reactive protein and kidney injury of anti-neutrophil cytoplasmic antibody associated vasculitis
Miaomiao ZHANG ; Pengcheng XU ; Shuiyi HU ; Li WEI ; Junya JIA ; Jianqing JIANG ; Tiekun YAN ; Shan LIN
Chinese Journal of Nephrology 2018;34(3):167-172
Objective To investigate the relationship between the incipient serum C-reactive protein (CRP) and clinicopathologic features in anti-neutrophil cytoplasmic antibody associated vasculitis (AAV).Methods Data of 138 consecutive AAV patients were collected.According to their serum CRP levels,patients were divided into group 1 with normal CRP,group 2 with slightly increased CRP and group 3 with severely increased CRP.Clinical features of AAV and histopathologic features of the kidney injury were compared among groups.Results CRP levels increased in 77.53% AAV patients on admission.Patients in the group of severely increased CRP had the highest levels of BVAS,serum C3,serum ANCA titer,leukocyte counts and the lowest levels of hemoglobin and albumin among the 3 groups (all P < 0.05).The mortality during the stage of therapy was highest in patients with severely increased CRP (P < 0.05).The focal kidney damage was more obvious in patients with severely increased CRP.There was no significant difference in renal prognosis among patients with different CRP levels.Conclusion The levels of incipient serum C-reactive protein of AAV vary in different patients and are positively correlated with patients' inflammation status as well as the disease activity,but are not correlated with the severity of kidney injury.
10. Pathologic features on gonadal changes of sexual developmental disorders in children
Peng YI ; Huilin NIU ; Qiu GAO ; Fenghua WANG ; Wei JIA ; Zhengrong CHEN ; Jianqing XIA ; Liping LI ; Yi CAO ; Rongxin ZENG
Chinese Journal of Pathology 2018;47(7):531-535
Objective:
To investigate the pathologic features of gonadal tissues of disorders of sexual development (DSD) in children.
Methods:
Fifty-three cases of gonadal developmental disorders were collected from July 2015 to August 2017 at Guangzhou Women and Children′s Medical Center. Clinical manifestations, karyotypes, sex hormone levels, ultrasound imaging, histology and immunophenotype of gonadal tissues were analyzed.
Results:
The age of patients ranged from 7 months to 17 years with an average of (50.7 ± 47.1) months. Social genders of the patients included 32 males and 21 females. Forty-eight patients had abnormal sex hormone levels. Clinical presentations included: toward female genitalia in 25 cases, male genitalia tendency in 17 cases and ambiguous external genitalia in 11 cases. Hypospadias was seen in 31 cases and short stature was seen in 8 cases. Chromosomal karyotyping of peripheral blood revealed 23 cases of sex chromosome disorders, 22 cases of 46 XY disorders, of which 3 cases were 5α-reductase deficiency and 8 cases of 46 XX disorders. Ultrasound examination showed cryptorchidism in 30 cases, including 16 cases of unilateral, 14 cases of bilateral and 1 case presenting a huge pelvic tumor. A total of 97 gonadal tissues from 53 cases of DSD were examined, including 9 cases of unilateral and 44 cases of bilateral gonads. Microscopically, 55 gonads (56.7%) showed dysplastic testes including 17 unilateral and 19 bilateral gonads. Fourteen were streak gonads (14.4%) including 8 unilateral and 3 bilateral gonadal tissues. Nine streak gonad with epithelial cord-like structures (9.3%) were found, of which 5 were unilateral and 2 were bilateral lesions. Seven gonads were ovotestis (7.2%), unilateral in 5 cases (the other side of the gonads of ovary in 4 cases, 1 case of dysplastic testes) and bilateral in 1 case. Seven gonads showed follicular-rich ovarian tissue (7.2%). One case showed bilateral dysplastic testes with gonadoblastoma and ectopic adrenal cortex. One case of streak gonad showed epithelial cord-like structures and undifferentiated glandular tissue embedded in malignant mixed germ cell tumors (mixed gonadoblastoma, dysgerminoma, mature teratoma and yolk sac tumor). One case had testicular microlithiasis. Uterus and fallopian tube structures were found in 11 cases. Immunohistochemical stains were performed in 15 cases. D2-40, PLAP and CKIT were expressed in germ cells and Calretinin, WT1 and inhibin were positive in Setoli cells. SALL4 and OCT3/4 were positive in 3 cases. Inhibin highlighted interstitial Leydig cells in 2 cases. GPC3 was positive in yolk sac tumor component.
Conclusions
Gonadal dysgenesis presents a broad spectrum of gonadal phenotypes with variable degrees of differentiation. The development of bilateral gonadal tissues has certain variability. Chromosomal karyotypes have no correlation with gonadal phenotypes. Accurate histopathologic diagnosis of gonadal dysgenesis plays an important role in the treatment and prognosis of the patient.

Result Analysis
Print
Save
E-mail